TCI Life Science News
Maximum quantity allowed is 999
Please select the quantity
October 2022
At TCI, we support discovery in life sciences through our knowledge and expertise in organic small molecules. This issue covers our life science topics as follows.
- Glycan-related Reagents for Virus Research: Sialic Acid derivatives, Sulfated Polysaccharides
- DSPE-PEG(2000)-Amine Ammonium Salt for the Preparation of Liposomes and Lipid Nanoparticles
- LDN-22684: A LRRK2 Inhibitor as a Useful Tool for the Study of Parkinson's Disease
- TCI Chemistry Research: TCIMAIL 190
Glycan-related Reagents for Virus Research: Sialic Acid Derivatives & Sulfated Polysaccharides
O-Acetylated sialic acids are involved in many viral infections and other diseases. TCI can offer partially modified sialic acid derivatives for infection or immunity research. On the other hand, sulfated polysaccharides act as multifunctional natural polysaccharides on cell surfaces and are involved in physiological functions in vivo. It has been widely reported in literature that these naturally- and chemically-sulfated polysaccharides have a strong effect on viral infections.
DSPE-PEG(2000)-Amine Ammonium Salt for the Preparation of Liposomes and Lipid Nanoparticles
DSPE-PEG(2000)-amine ammonium salt [D6011] is a synthetic phospholipid formed via modification of the hydrophobic head group of DSPE with an aminated PEG. The PEG moiety of D6011 confers improved biocompatibility, while the terminal amine group allows for quick and easy attachment to other molecules containing appropriate functional groups. D6011 is primarily used as a major component for the preparation of liposomes and lipid nanoparticles in drug delivery systems (DDS); it has been used to develop targeted therapies against cancer / cancer cell mitochondria, Alzheimer's disease, as well as photodynamic therapy and thermo-chemotherapy. Additionally, it has also been applied in areas other than drug delivery, like molecular targeted imaging.
LDN-22684: A LRRK2 Inhibitor as a Useful Tool for the Study of Parkinson's Disease
The leucine-rich repeat kinase 2 (LRRK2) is a large protein (2527 amino acids) with serine-threonine (Ser/Thr) protein kinase activity and autophosphorylation activity. It is highly expressed in many mammal tissues. Genetic mutations in the G2019S encoding portion of LRRK2 (LRRK2-G2019S) have been frequently detected in patients with Parkinson's disease (PD). As a result, inhibitors targeting LRRK2 (especially those selective for the G2019S variant) have been increasingly researched recently not only as a treatment for familial PD, but also as a useful tool to study LRRK2 functions. It is reported that LDN-22684 [L0422] inhibited LRRK2-G2019S and wild-type LRRK2 in the micromolar range.
TCI Chemistry Research: TCIMAIL 190
Released in August 2022, TCI's latest issue features Asst. Prof. Yuki Sakamoto’s article and Prof. Nagatoshi Nishiwaki’s chemistry chat. We also feature research on: » TCI eNewsletter Back IssuesFollow Us on Social Media
|
|
|
|
How to Order TCI ProductsTo order, please contact your local distributor found below.» Our distributors |
| * The prices displayed in the landing website are USD based catalog prices. TCI has specific website and local currency based price list for customers in South Korea, Singapore, and Australia. For customers in other Asia Pacific countries / regions, please visit our Asia Pacific Website and contact our local distributors for the end user's cost. (The USD prices that are shown in Asia Pacific websites are TCI's catalog prices.) Please visit each country/region's website from the following links and confirm the prices. https://www.TCIchemicals.com |
|
If you are interested in our biweekly e-enewsletter "TCI News" and want to receive regularly, please click the link below and sign up. TCI News Sign-Up |
|
Tokyo Chemical Industry Co., Ltd. (TCI) Global Business Department Customer Support and Technical service » globalbusiness@TCIchemicals.com » https://www.TCIchemicals.com |